News | August 12, 2021
Natco Pharma PAT at Rs 75 crore for Q1FY22
The company has strong product launches both in India and overseas
The company has strong product launches both in India and overseas
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
A veteran in cell therapy and oncology commercialisation
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The transaction is expected to close in the Q4FY22
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Subscribe To Our Newsletter & Stay Updated
